Latest News & Features
Refine Search
Asia
 Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.   9 September 2021 
Americas
 Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.   9 September 2021 
Big Pharma
 Australia will waive IP protections for COVID-19 vaccines to enable more cost-effective copycat versions to be manufactured in developing countries, in the wake of mounting pressure from human rights groups and governments worldwide.   9 September 2021 
Medtech
 Advanced Biologics has managed to convince the English High Court to expedite a patent infringement and validation suit it is embroiled in with German rival Med-El.   9 September 2021 
Plant Varieties
 International law firm Haynes Boone has launched the CBD Hemp Industry Group to advise businesses on the burgeoning cannabinoid market.   8 September 2021 
Americas
 Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.   7 September 2021 
Americas
 Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.   7 September 2021 
Americas
 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.   6 September 2021 
Medtech
 The US District Court for the Northern District of California has denied an attempt by Chinese company BGI Genomics to invalidate an Illumina DNA sequencing patent in a summary judgment, leaving the dispute over infringement of another Illumina patent to be decided at trial.   2 September 2021 
Americas
 Belcher’s chief science officer deceived the US Patent and Trademark Office in order to obtain a patent, the US Court of Appeals for the Federal Circuit has ruled in a win for Pfizer’s subsidiary, Hospira.   2 September 2021 


